Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM)

被引：0
|
作者：
Montazeri, Kamaneh
Davar, Diwakar
Haymaker, Cara L.
Sheth, Rahul
Kuban, Joshua
Weintraub, Joshua
Wehrenberg-Klee, Eric
Novelli, Paula M.
Gonsalves, Carin F.
Adamo, Robert D.
Lucci, Anthony
Meas, Salyna
Sarli, Vanessa Nicole
Prieto, Victor Gerardo
Geller, David A.
Orloff, Marlana M.
Carvajal, Richard D.
Patel, Sapna Pradyuman
机构：
[1] Massachusetts Gen Hosp, Boston, PA USA
[2] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Columbia Univ, Irving Med Ctr, New York, NY USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Jefferson, Philadelphia, PA USA
[7] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA
[8] Univ Pittsburgh, Med Ctr Liver Canc Ctr, Pittsburgh, PA USA
[9] Columbia Univ, Med Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2521
引用
收藏
页数：1
相关论文
共 3 条
  • [1] PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure-enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101+/- checkpoint inhibition in metastatic uveal melanoma
    Patel, Sapna P.
    Haymaker, Cara
    Sheth, Rahul A.
    Kuban, Joshua D.
    Weintraub, Joshua
    Wehrenberg-Klee, Eric
    Novelli, Paula
    Gonsalves, Carin
    Adamo, Robert
    Honaker, Virgina
    Timciuc, Laura
    Hennegan, Tarin
    Molina, Juan C. Amador
    Duose, Dzifa
    Cuenta, Edwin R. Parras
    Lucci, Anthony
    Meas, Salyna
    Sarli, Vanessa
    Prieto, Victor G.
    LaPorte, Jason
    Hulstine, Ann-Marie
    Moody, Ashley
    Cox, Bryan
    Geller, David
    Davar, Diwakar
    Montazeri, Kamaneh
    Orloff, Marlana
    Katz, Steven C.
    Carvajal, Richard
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Impact of Pressure-Enabled Drug Delivery (PEDD) of Nelitolimod (SD-101) into the Liver with Systemic Immune Checkpoint Inhibitor (ICI) for Treating Metastatic Uveal Melanoma with Liver Metastases (MUM-LM)
    Layman, Ilan
    Ghosh, Chandra C.
    Cournoyer, Lauren
    Guha, Prajna
    Laporte, Jason
    Ballarin, Alizee
    Morrissey, Molly
    Fraser, Kayla M.
    Cox, Bryan F.
    Katz, Steven C.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2024, 239 (05) : S446 - S446
  • [3] PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion plus /-checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
    Lee, Sunyoung S.
    Almhanna, Khaldoun
    Sheth, Rahul
    Pant, Shubham
    Kuban, Joshua
    Maxwell, Aaron Wilhelm Palmer
    Witt, Brian Justin
    LaPorte, Jason
    Hulstine, Ann-Marie
    Cox, Bryan
    Carvajal, Richard D.
    White, Ruth Aroon
    Weintraub, Joshua
    Davis, Lindsey
    Hart, James
    Knight, Robert D.
    Katz, Steven C.
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1